Clinical Trial Update: A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

A Phase 3 head-to-head trial comparing oral upadacitinib with subcutaneous dupilumab in adolescents and adults with moderate-to-severe atopic dermatitis, with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)
• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2025-02-14